The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The occurrence of brain metastasis (BM) has increased due to improved overall survival (OS) in uterine cervical cancer. However, research about prognostic factors and therapeutic guidelines for BM in uterine cervical cancer remains scarce due to the rarity of BM in this type of cancer. The present study evaluated the clinical characteristics and prognostic factors influencing OS in patients with BM from uterine cervical cancer. Methods: A total of 19 BM patients of uterine cervical cancer were analyzed retrospectively from January 1995 to December 2016. Results: The median and mean OS of all patients was 9.6 and 15.4 months. Treatment (vs. palliative care, p < 0.001), fewer than three regimens of chemotherapy before BM (vs. ≥ 3, p < 0.013), and chemotherapy after BM (vs. absence, p < 0.001) significantly increased the OS time. The Karnofsky performance status ≥ 70 (vs. < 70, p = 0.213), single BM (vs. multiple BM, p = 0.157), and small cell carcinoma (vs. others, p = 0.351) had numerically higher OS than others. Dual therapy (vs. single therapy, p = 0.182; vs. no therapy, p = 0.076) were associated with a longer OS time, but the difference did not reach statistical significance. In addition, the graded prognostic assessment (GPA) appeared to be a better prognostic tool than the recursive partitioning analysis. Conclusions: The results of the present study suggest active multimodal treatment including neurosurgery, radiotherapy, and chemotherapy for BM of uterine cervical cancer with single BM, good performance status, histology of small cell carcinoma, and a better GPA.
Abstract
Background/Aims: The occurrence of brain metastasis (BM) has increased due to improved overall survival (OS) in uterine cervical cancer. However, research about prognostic factors and therapeutic guidelines for BM in uterine cervical cancer remains scarce due to the rarity of BM in this type of cancer. The present study evaluated the clinical characteristics and prognostic factors influencing OS in patients with BM from uterine cervical cancer. Methods: A total of 19 BM patients of uterine cervical cancer were analyzed retrospectively from January 1995 to December 2016. Results: The median and mean OS of all patients was 9.6 and 15.4 months. Treatment (vs. palliative care, p < 0.001), fewer than three regimens of chemotherapy before BM (vs. ≥ 3, p < 0.013), and chemotherapy after BM (vs. absence, p < 0.001) significantly increased the OS time. The Karnofsky performance status ≥ 70 (vs. < 70, p = 0.213), single BM (vs. multiple BM, p = 0.157), and small cell carcinoma (vs. others, p = 0.351) had numerically higher OS than others. Dual therapy (vs. single therapy, p = 0.182; vs. no therapy, p = 0.076) were associated with a longer OS time, but the difference did not reach statistical significance. In addition, the graded prognostic assessment (GPA) appeared to be a better prognostic tool than the recursive partitioning analysis. Conclusions: The results of the present study suggest active multimodal treatment including neurosurgery, radiotherapy, and chemotherapy for BM of uterine cervical cancer with single BM, good performance status, histology of small cell carcinoma, and a better GPA.
참고문헌 (23)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
- Sato Y, "Uterine cervical cancer with brain metastasis as the initial site of presentation", J Obstet Gynaecol Res, 41, pp.1145~1148 (2015)
- Ogawa K, "Treatment and prognosis of brain metastases from gynecological cancers", Neurol Med Chir(Tokyo), 48, pp.57~62 (2008)
- Bindal RK, "Surgical treatment of multiple brain metastases", J Neurosurg, 79, pp.210~216 (1993)
- Teke F, "The impact of the stage and tumor size on rare brain metastasis of cervical cancer", Turk Neurosurg, 26, pp.818~823 (2016)
- Richards GM, "Therapeutic management of metastatic brain tumors", Crit Rev Oncol Hematol, 61, pp.70~78 (2007)
- Hayashi N, "A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer", BMC Cancer, 17, pp.397~ (2017)
- Venur VA, "Prognostic scores for brain metastasis patients : use in clinical practice and trial design", Chin Clin Oncol, 4, pp.18~ (2015)
- Gaspar L, "Recursive partitioning analysis(RPA)of prognostic factors in three Radiation Therapy Oncology Group(RTOG)brain metastases trials", Int J Radiat Oncol Biol Phys, 37, pp.745~751 (1997)
- Sperduto CM, "A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment", J Neurosurg, (109 Suppl), pp.87~89 (2008)
- Piura E, "Brain metastases from cervical carcinoma : overview of pertinent literature", Eur J Gynaecol Oncol, 33, pp.567~573 (2012)
- 김영준, "A Clinical Analysis of Brain Metastasis in Gynecologic Cancer: A Retrospective Multi-institute Analysis", Journal of Korean Medical Science, 30(1), pp.66~73 (2015), 대한의학회
- Hwang JH, "Brain metastasis in patients with uterine cervical cancer", J Obstet Gynaecol Res, 39, pp.287~291 (2013)
- Tewari KS, "Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with", without bevacizumab : NRG Oncology, Clin Cancer Res, pp.2015, 21[DOI]
- Nasu K, "Clinicopathologic features of brain metastases from gynecologic malignancies : a retrospective study of 139 cases(KCOG-G1001s trial)", Gynecol Oncol, 128, pp.198~203 (2013)
- Chura JC, "Brain metastasis from cervical carcinoma", Int J Gynecol Cancer, 17, pp.141~146 (2007)
- Satoh T, "Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix", Int J Gynecol Cancer, 24(9 Suppl 3), pp.S102~S108 (2014)
- Zivanovic O, "Small cell neuroendocrine carcinoma of the cervix : analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy", Gynecol Oncol, 112, pp.590~593 (2009)
- Gardner GJ, "Neuroendocrine tumors of the gynecologic tract : a Society of Gynecologic Oncology(SGO)clinical document", Gynecol Oncol, 122, pp.190~198 (2011)
- Tabouret E, "Assessment of prognostic scores in brain metastases from breast cancer", Neuro Oncol, 16, pp.421~428 (2014)
- Luo J, "Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy", Int J Clin Exp Med, 7, pp.5217~5225 (2014)
- Sperduto PW, "Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases : a multi-institutional analysis of 4, 259 patients", Int J Radiat Oncol Biol Phys, 77, pp.655~661 (2010)